Solventum (NYSE:SOLV) Now Covered by Wedbush

Wedbush initiated coverage on shares of Solventum (NYSE:SOLV) in a report published on Friday, MarketBeat.com reports. The brokerage issued an outperform rating and a $94.00 price target on the stock.

Several other research firms have also recently issued reports on SOLV. UBS Group cut shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research report on Thursday. Wells Fargo & Company decreased their price objective on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 6th. Rothschild & Co Redburn began coverage on shares of Solventum in a research report on Tuesday, March 24th. They set a “sell” rating and a $60.00 price objective for the company. Mizuho set a $100.00 price objective on shares of Solventum and gave the stock an “outperform” rating in a research report on Tuesday, January 20th. Finally, BTIG Research reaffirmed a “buy” rating and set a $89.00 price objective on shares of Solventum in a research report on Wednesday, May 6th. Eight analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $84.25.

Solventum Stock Performance

Shares of SOLV stock opened at $74.26 on Friday. The stock has a market capitalization of $12.86 billion, a PE ratio of 9.10, a P/E/G ratio of 1.15 and a beta of 0.59. The firm has a 50 day moving average of $67.94 and a two-hundred day moving average of $74.56. Solventum has a 52 week low of $62.38 and a 52 week high of $88.20. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.35 by $0.13. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The company’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, research analysts predict that Solventum will post 6.58 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Amy Mcbride Wendell purchased 1,475 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The shares were purchased at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the purchase, the director directly owned 5,039 shares of the company’s stock, valued at $342,803.17. The trade was a 41.39% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.24% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Solventum

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Solventum by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock worth $1,249,847,000 after acquiring an additional 867,837 shares in the last quarter. Independent Franchise Partners LLP raised its stake in Solventum by 19.0% during the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock worth $1,216,785,000 after acquiring an additional 2,456,451 shares in the last quarter. State Street Corp raised its stake in Solventum by 2.0% during the 4th quarter. State Street Corp now owns 6,344,761 shares of the company’s stock worth $502,759,000 after acquiring an additional 124,490 shares in the last quarter. Davis Selected Advisers raised its stake in Solventum by 12.7% during the 4th quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock worth $492,880,000 after acquiring an additional 702,461 shares in the last quarter. Finally, Boston Partners raised its stake in Solventum by 26.1% during the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after acquiring an additional 959,543 shares in the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.